文献速递白血病

UGT1A1基因型影响中危急性髓系白血病患者接受阿糖胞苷化疗的临床结局

UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy.
PubMed 文献 · Leukemia · 2020-03-09

该研究纳入455例接受阿糖胞苷为基础化疗的中危细胞遗传学急性髓系白血病患者,分析UGT1A1 rs8175347基因型与临床结局的关联。UGT1A1*28纯合变异(与较低UGT1A1活性相关)患者的总生存率更低(25.8% vs. 45.5%;p=0.004),多因素分析证实该关联(p=0.008;HR=1.79;95%CI:1.16-2.76)。亚组分析显示该负效应在女性中显著(14.8% vs. 52.7%;p=0.001),男性中不显著。

要点

  • UGT1A1*28纯合变异与中危AML患者阿糖胞苷化疗后更低的总生存率相关。
  • 该负效应主要在女性患者中显著,男性中未观察到。
  • 低UGT1A1活性可能与巩固化疗后中性粒细胞减少延长及未复发死亡增加相关。

核心结论

  • UGT1A1*28纯合变异与接受阿糖胞苷为基础化疗的中危细胞遗传学AML患者更低的总生存率独立相关。

研究设计与样本

  • 研究纳入455例接受阿糖胞苷为基础化疗的中危细胞遗传学急性髓系白血病患者,分析UGT1A1 rs8175347基因型与临床结局的关联。

主要发现

  • UGT1A1*28纯合变异患者的总生存率显著低于其他基因型患者(25.8% vs. 45.5%;p=0.004)。
  • 多因素分析证实UGT1A1*28纯合变异与总生存率降低独立相关(p=0.008;HR=1.79;95%CI:1.16-2.76)。
  • 亚组分析显示UGT1A1*28纯合变异对总生存率的负效应在女性中显著(14.8% vs. 52.7%;p=0.001),男性中不显著。
  • 较低的总生存率与巩固化疗后中性粒细胞减少时间延长及未复发死亡增加相关。

临床怎么用

  • 对于接受阿糖胞苷为基础化疗的中危AML患者,UGT1A1 rs8175347基因型检测可能有助于识别总生存预后较差的患者,尤其是女性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The treatment of acute myeloid leukemia (AML) is adjusted according to cytogenetic risk factors and molecular markers. Cytarabine remains the main drug to treat AML, and several studies have explored the prognostic relevance of the genotype of cytarabine metabolizing enzymes in AML. Glucuronidation has been identified to be relevant in the cytarabine clearance, but there are still few data concerning the clinical impact of genetic polymorphisms known to condition the activity of UDP-glucuronosyl transferases in AML patients. Here we report the association between the UGT1A1 rs8175347 genotype and the clinical outcome of 455 intermediate-risk cytogenetic AML patients receiving cytarabine-based chemotherapy. Patients with the UGT1A1*28 homozygous variant (associated to a lower UGT1A1 activity) had a lower overall survival (OS) (25.8% vs. 45.5%; p: 0.004). Multivariate analysis confirmed this association (p: 0.008; HR: 1.79; 95% CI: 1.16-2.76). Subgroup analysis showed the negative effect of the UGT1A1*28 homozygous genotype on OS in women (14.8% vs. 52.7%; p: 0.001) but not in men. This lower OS was associated with longer neutropenia after consolidation chemotherapy and with higher mortality without previous relapse, suggesting an association between a low glucuronidation activity and mortal toxic events.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Díaz-Santa J, Rodríguez-Romanos R, Osca G, et al. UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy. Leukemia. 2020. PMID: 32152464. doi:10.1038/s41375-020-0784-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。